187 related articles for article (PubMed ID: 34193711)
21. Phthalazinones 2: Optimisation and synthesis of novel potent inhibitors of poly(ADP-ribose)polymerase.
Cockcroft XL; Dillon KJ; Dixon L; Drzewiecki J; Kerrigan F; Loh VM; Martin NM; Menear KA; Smith GC
Bioorg Med Chem Lett; 2006 Feb; 16(4):1040-4. PubMed ID: 16290932
[TBL] [Abstract][Full Text] [Related]
22. An evaluation in vitro of PARP-1 inhibitors, rucaparib and olaparib, as radiosensitisers for the treatment of neuroblastoma.
Nile DL; Rae C; Hyndman IJ; Gaze MN; Mairs RJ
BMC Cancer; 2016 Aug; 16():621. PubMed ID: 27515310
[TBL] [Abstract][Full Text] [Related]
23. Structure-Guided Design and In-Cell Target Profiling of a Cell-Active Target Engagement Probe for PARP Inhibitors.
Howard RT; Hemsley P; Petteruti P; Saunders CN; Molina Bermejo JA; Scott JS; Johannes JW; Tate EW
ACS Chem Biol; 2020 Feb; 15(2):325-333. PubMed ID: 32017532
[TBL] [Abstract][Full Text] [Related]
24. In Silico Screening Identifies a Novel Potential PARP1 Inhibitor Targeting Synthetic Lethality in Cancer Treatment.
Li J; Zhou N; Cai P; Bao J
Int J Mol Sci; 2016 Feb; 17(2):258. PubMed ID: 26907257
[TBL] [Abstract][Full Text] [Related]
25. Discovery and Characterization of (8S,9R)-5-Fluoro-8-(4-fluorophenyl)-9-(1-methyl-1H-1,2,4-triazol-5-yl)-2,7,8,9-tetrahydro-3H-pyrido[4,3,2-de]phthalazin-3-one (BMN 673, Talazoparib), a Novel, Highly Potent, and Orally Efficacious Poly(ADP-ribose) Polymerase-1/2 Inhibitor, as an Anticancer Agent.
Wang B; Chu D; Feng Y; Shen Y; Aoyagi-Scharber M; Post LE
J Med Chem; 2016 Jan; 59(1):335-57. PubMed ID: 26652717
[TBL] [Abstract][Full Text] [Related]
26. Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances anti-tumor effects of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in triple-negative breast cancer cells.
Min A; Im SA; Kim DK; Song SH; Kim HJ; Lee KH; Kim TY; Han SW; Oh DY; Kim TY; O'Connor MJ; Bang YJ
Breast Cancer Res; 2015 Mar; 17():33. PubMed ID: 25888415
[TBL] [Abstract][Full Text] [Related]
27. Structure-based design of new poly (ADP-ribose) polymerase (PARP-1) inhibitors.
Chadha N; Jaggi AS; Silakari O
Mol Divers; 2017 Aug; 21(3):655-660. PubMed ID: 28653128
[TBL] [Abstract][Full Text] [Related]
28. Examination of Diazaspiro Cores as Piperazine Bioisosteres in the Olaparib Framework Shows Reduced DNA Damage and Cytotoxicity.
Reilly SW; Puentes LN; Wilson K; Hsieh CJ; Weng CC; Makvandi M; Mach RH
J Med Chem; 2018 Jun; 61(12):5367-5379. PubMed ID: 29856625
[TBL] [Abstract][Full Text] [Related]
29. A rapid fluorescent method for the real-time measurement of poly(ADP-ribose) polymerase 1 activity.
Kurgina TA; Anarbaev RO; Sukhanova MV; Lavrik OI
Anal Biochem; 2018 Mar; 545():91-97. PubMed ID: 29326071
[TBL] [Abstract][Full Text] [Related]
30. Folliculin deficient renal cancer cells exhibit BRCA1 A complex expression impairment and sensitivity to PARP1 inhibitor olaparib.
Zhang Q; Xu Y; Zhang Z; Li J; Xia Q; Chen Y
Gene; 2021 Feb; 769():145243. PubMed ID: 33069804
[TBL] [Abstract][Full Text] [Related]
31. Olaparib hydroxamic acid derivatives as dual PARP and HDAC inhibitors for cancer therapy.
Yuan Z; Chen S; Sun Q; Wang N; Li D; Miao S; Gao C; Chen Y; Tan C; Jiang Y
Bioorg Med Chem; 2017 Aug; 25(15):4100-4109. PubMed ID: 28601509
[TBL] [Abstract][Full Text] [Related]
32. Synthesis of Some Benzimidazole-derived Molecules and their Effects on PARP-1 Activity and MDA-MB-231, MDA-MB-436, MDA-MB-468 Breast Cancer Cell Viability.
Gurkan-Alp AS; Alp M; Karabay AZ; Koc A; Buyukbingol E
Anticancer Agents Med Chem; 2020; 20(14):1728-1738. PubMed ID: 32357823
[TBL] [Abstract][Full Text] [Related]
33. Stereospecific PARP trapping by BMN 673 and comparison with olaparib and rucaparib.
Murai J; Huang SY; Renaud A; Zhang Y; Ji J; Takeda S; Morris J; Teicher B; Doroshow JH; Pommier Y
Mol Cancer Ther; 2014 Feb; 13(2):433-43. PubMed ID: 24356813
[TBL] [Abstract][Full Text] [Related]
34. Crystal structure-based discovery of a novel synthesized PARP1 inhibitor (OL-1) with apoptosis-inducing mechanisms in triple-negative breast cancer.
Fu L; Wang S; Wang X; Wang P; Zheng Y; Yao D; Guo M; Zhang L; Ouyang L
Sci Rep; 2016 Dec; 6(1):3. PubMed ID: 28442756
[TBL] [Abstract][Full Text] [Related]
35. Novel 4,5-dihydrospiro[benzo[c]azepine-1,1'-cyclohexan]-3(2H)-one derivatives as PARP-1 inhibitors: Design, synthesis and biological evaluation.
Li S; Li XY; Zhang TJ; Zhu J; Liu KL; Wang DP; Meng FH
Bioorg Chem; 2021 Jun; 111():104840. PubMed ID: 33780687
[TBL] [Abstract][Full Text] [Related]
36. Design, synthesis and biological evaluation of novel molecules as potent PARP-1 inhibitors.
Shen H; Ge Y; Wang J; Li H; Xu Y; Zhu Q
Bioorg Med Chem Lett; 2021 Sep; 47():128169. PubMed ID: 34091044
[TBL] [Abstract][Full Text] [Related]
37. Radiosensitization with an inhibitor of poly(ADP-ribose) glycohydrolase: A comparison with the PARP1/2/3 inhibitor olaparib.
Gravells P; Neale J; Grant E; Nathubhai A; Smith KM; James DI; Bryant HE
DNA Repair (Amst); 2018 Jan; 61():25-36. PubMed ID: 29179156
[TBL] [Abstract][Full Text] [Related]
38. Efficacy of poly (ADP-ribose) polymerase inhibitor olaparib against head and neck cancer cells: Predictions of drug sensitivity based on PAR-p53-NF-κB interactions.
Kwon M; Jang H; Kim EH; Roh JL
Cell Cycle; 2016 Nov; 15(22):3105-3114. PubMed ID: 27686740
[TBL] [Abstract][Full Text] [Related]
39. Design, synthesis, and biological evaluation of novel chrysin derivatives as poly(ADP-ribose) polymerase 1 (PARP1) inhibitors for the treatment of breast cancer.
Yang Y; Tong J; Xie X; Cao H; Fu Y; Luo Y; Liu S; Chen W; Yang N
Chin J Nat Med; 2024 May; 22(5):455-465. PubMed ID: 38796218
[TBL] [Abstract][Full Text] [Related]
40. Identification of novel PARP-1 inhibitors: Drug design, synthesis and biological evaluation.
Xie Z; Zhou Y; Zhao W; Jiao H; Chen Y; Yang Y; Li Z
Bioorg Med Chem Lett; 2015 Oct; 25(20):4557-61. PubMed ID: 26342868
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]